Kenshi Suzuki

ORCID

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 8

Top Venues

Annals of hematology

Blood advances

Leukemia

International journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Paul Gerard Richardson, Thierry Facon, Christopher P Venner, Nizar J Bahlis, Fritz Offner, Darrell White, Lionel Karlin, Lotfi Benboubker, Eric Voog, Sung-Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Miguel Villarreal, Philip Twumasi-Ankrah, Richard Labotka, Robert M Rifkin, Sagar Lonial, Shaji K Kumar, S Vincent Rajkumar, Philippe Moreau
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial. EJHaem 4 (4) (2023)
Andrew Spencer, Philippe Moreau, Maria-Victoria Mateos-Manteca, Hartmut Goldschmidt, Kenshi Suzuki, Mark-David Levin, Pieter Sonneveld, Robert Z Orlowski, Sung Soo Yoon, Saad Z Usmani, Katja C Weisel, Donna Reece, Tahamtan Ahmadi, Huiling Pei, Wendy Garvin Mayo, Xue Gai, Jodi Carey, J Blake Bartlett, Robin Carson, Meletios-Athanasios A Dimopoulos
Daratumumab in Myeloma Patients With Early or Late Relapse After Initial Therapy: Subgroup Analysis of CASTOR and POLLUX. Blood advances (2023)
Yu Abe, Makoto Sasaki, Naoki Takezako, Shigeki Ito, Kazuhito Suzuki, Hiroshi Handa, Takaaki Chou, Takahiro Yoshida, Ikuo Mori, Tomohiro Shinozaki, Kenshi Suzuki
Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma. Annals of hematology (2023)
Yu Abe, Makoto Sasaki, Naoki Takezako, Shigeki Ito, Kazuhito Suzuki, Hiroshi Handa, Takaaki Chou, Takahiro Yoshida, Ikuo Mori, Tomohiro Shinozaki, Kenshi Suzuki
Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma. Annals of hematology (2023)
Thomas Martin, Joseph R Mikhael, Roman Hájek, Kihyun Kim, Kenshi Suzuki, Cyrille Hulin, Mamta Garg, Hang Quach, Hanlon Sia, Anup George, Tatyana S Konstantinova, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Helgi van de Velde, Philippe Moreau
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. Blood advances 6 (15) (2022)
Kenshi Suzuki, Chang-Ki Min, Kihyun Kim, Je-Jung Lee, Hirohiko Shibayama, Po-Shen Ko, Shang-Yi Huang, Sin-Syue Li, Bifeng Ding, Monica Khurana, Shinsuke Iida
Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial. International journal of hematology 114 (6) (2021)
Thierry Facon, Christopher P Venner, Nizar J Bahlis, Fritz Offner, Darrell J White, Lionel Karlin, Lofti Benboubker, Sophie Rigaudeau, Philippe Rodon, Eric Voog, Sung Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Philip Twumasi-Ankrah, Godwin Yung, Robert M Rifkin, Philippe Moreau, Sagar Lonial, Shaji K Kumar, Paul G Richardson, Sundararajan Vincent Rajkumar
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 137 (26) (2021)
Angela Dispenzieri, Efstathios Kastritis, Ashutosh D Wechalekar, Stefan O Schönland, Kihyun Kim, Vaishali Sanchorawala, Heather J Landau, Fiona Kwok, Kenshi Suzuki, Raymond L Comenzo, Deborah Berg, Guohui Liu, Arun Kumar, Douglas V Faller, Giampaolo Merlini
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. Leukemia (2021)

Kenshi Suzuki.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Kenshi Suzuki